|
EIF4G3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.57069954002054E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.66550000141919E-08 |
| Normal-vs-Stage2 |
6.419500E-03 |
| Normal-vs-Stage3 |
2.09390282890354E-11 |
| Normal-vs-Stage4 |
2.40230058068391E-11 |
| Stage1-vs-Stage2 |
1.207590E-01 |
| Stage1-vs-Stage3 |
6.517100E-03 |
| Stage1-vs-Stage4 |
2.076700E-03 |
| Stage2-vs-Stage3 |
1.421780E-03 |
| Stage2-vs-Stage4 |
1.156210E-03 |
| Stage3-vs-Stage4 |
6.496400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.81510411940189E-11 |
| Normal-vs-AfricanAmerican |
9.640900E-04 |
| Normal-vs-Asian |
2.58070000036525E-07 |
| Caucasian-vs-AfricanAmerican |
4.017600E-01 |
| Caucasian-vs-Asian |
7.457000E-01 |
| AfricanAmerican-vs-Asian |
5.359200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.94550000740679E-09 |
| Normal-vs-Female |
2.81580003758108E-09 |
| Male-vs-Female |
3.325400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.61900000364923E-08 |
| Normal-vs-Age(41-60Yrs) |
9.40030000506908E-08 |
| Normal-vs-Age(61-80Yrs) |
3.33139960062567E-10 |
| Normal-vs-Age(81-100Yrs) |
5.61040000000013E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.959000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.521800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.694000E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.145800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.972780E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.353190E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.176430E-04 |
| Classical-VS-Follicular |
4.004100E-03 |
| Classical-VS-Other |
4.687200E-01 |
| Classical-VS-Normal |
3.11690007137599E-10 |
| Tall-VS-Follicular |
1.58440000008753E-07 |
| Tall-VS-Other |
3.181800E-01 |
| Tall-VS-Normal |
5.19806420129498E-13 |
| Follicular-VS-Other |
1.533550E-02 |
| Follicular-VS-Normal |
1.180300E-02 |
| Other-VS-Normal |
1.639870E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.20110000021579E-07 |
| Normal-vs-N1 |
1.50820000932583E-09 |
| N0-vs-N1 |
4.293800E-02 |
|
|
